Surgery for hyperparathyroidism in image-negative patients

Arch Surg. 2008 Apr;143(4):335-7. doi: 10.1001/archsurg.143.4.335.

Abstract

Hypothesis: Patients with primary hyperparathyroidism and negative preoperative localization imaging have a different outcome than patients with positive imaging.

Design: Prospective single-surgeon case series.

Setting: Referral center.

Patients: Forty-two patients with primary hyperparathyroidism, indications for surgery, and both cervical ultrasonographic results and technetium Tc 99m sestamibi nuclear images that were nonlocalizing over a 5- year span.

Main outcome measures: Extent of surgery required to produce cure; operative findings.

Results: Of 430 patients undergoing surgery for primary hyperparathyroidism, 351 underwent both ultrasonographic and sestamibi imaging. Among 351 patients, the imaging results of 42 patients did not show an adenoma, and these patients underwent cervical exploratory surgery. Of 42 patients, 41 were cured at a mean follow-up of 90 days; 1 patient underwent surgical reexploration and was cured by removal of a mediastinal adenoma. To achieve initial cure, 12 of 42 patients (28.6%) required partial thyroidectomy, 9 (21.4%) required partial thymectomy, 17 (40.5%) required paratracheal dissection to access or devascularize an obscure adenoma. Pathologic examination disclosed single adenoma in 26 of 42 patients (61.9%), parathyroid hyperplasia in 14 (33.3%), and double adenoma in 2 (4.8%).

Conclusions: Patients whose preoperative localization studies fail to localize solitary adenoma commonly require extensive surgery to cure hyperparathyroidism. Lack of localization may be a reasonable criterion on which to base referral of the patient to a high-volume medical center.

MeSH terms

  • Analysis of Variance
  • Humans
  • Hyperparathyroidism, Primary / diagnostic imaging
  • Hyperparathyroidism, Primary / surgery*
  • Prospective Studies
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi
  • Thyroidectomy
  • Treatment Outcome
  • Ultrasonography

Substances

  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi